# RGS7

Source: https://onco.cc/targets/rgs7/  
OnCo record `rgs7` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RGS7 (Regulator of G protein signalling 7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Non-small-cell lung cancer and Melanoma.

## Summary

GTPase activator component of the RGS7-GNB5 complex that regulates G protein-coupled receptor signalling cascades. The RGS7-GNB5 complex acts as an inhibitor signal transduction by promoting the GTPase activity of G protein alpha subunits, such as GNAO1, thereby driving them into their inactive GDP-bound form. May play a role in synaptic vesicle exocytosis.

IntOGen calls it a driver in 6 cohorts (4 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Melanoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: regulator of G protein signaling 7; Regulator of G protein signaling 7
- Tags: cancer-genes-wave
- Symbol: RGS7
- Class: oncogene
- Biology: GTPase activator component of the RGS7-GNB5 complex that regulates G protein-coupled receptor signalling cascades. The RGS7-GNB5 complex acts as an inhibitor signal transduction by promoting the GTPase activity of G protein alpha subunits, such as GNAO1, thereby driving them into their inactive GDP-bound form. May play a role in synaptic vesicle exocytosis. Glycine-dependent regulation of the RGS7-GNB5 complex by GPR158 affects mood and cognition via its ability to regulate neuronal excitability in L2/L3 pyramidal neurons of the prefrontal cortex. Modulates the activity of potassium channels that are activated by GNAO1 in response to muscarinic acetylcholine receptor M2/CHRM2 signalling. Location: Cytoplasm, cytosol; Cytoplasm; Cell membrane; Membrane (UniProt). Locus 1q43 (HGNC).
- Where found: Breast cancer: IntOGen driver in 1 cohort (BRCA); Non-small-cell lung cancer: IntOGen driver in 3 cohorts (LUAD, LUSC); Melanoma: IntOGen driver in 2 cohorts (MEL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10003: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10003
- UniProt P49802: https://www.uniprot.org/uniprotkb/P49802/entry
- NCBI Gene 6000: https://www.ncbi.nlm.nih.gov/gene/6000
- Ensembl ENSG00000182901: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182901

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/rgs7.json